James M. Frates
Chief Financial Officer · Amylyx Pharmaceuticals, Inc.
- 2025
- Sep 14, 2026
- 10
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies James M. Frates files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Joshua B. Cohen - $3.60M in AMLX purchases and sales in the last 12 months
- Justin B. Klee - $3.59M in AMLX purchases and sales in the last 12 months
- Gina Mazzariello - $1.05M in AMLX purchases and sales in the last 12 months
- George M. Milne Jr. - $831K in AMLX purchases and sales in the last 12 months
- Camille L. Bedrosian - $513K in AMLX purchases and sales in the last 12 months
- Karen Firestone - $152K in AMLX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is James M. Frates?
James M. Frates is a corporate insider, tracked as Chief Financial Officer of Amylyx Pharmaceuticals, Inc. (AMLX). InsiderAlpha holds 10 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has James M. Frates submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has James M. Frates been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($746K) across all tracked filings.
